CA2504751C - Procedes servant a traiter le reflux gastro-oesophagien pathologique - Google Patents

Procedes servant a traiter le reflux gastro-oesophagien pathologique Download PDF

Info

Publication number
CA2504751C
CA2504751C CA2504751A CA2504751A CA2504751C CA 2504751 C CA2504751 C CA 2504751C CA 2504751 A CA2504751 A CA 2504751A CA 2504751 A CA2504751 A CA 2504751A CA 2504751 C CA2504751 C CA 2504751C
Authority
CA
Canada
Prior art keywords
use according
glucocorticoid receptor
gastroesophageal reflux
antagonist
reflux disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2504751A
Other languages
English (en)
Other versions
CA2504751A1 (fr
Inventor
Joseph K. Belanoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of CA2504751A1 publication Critical patent/CA2504751A1/fr
Application granted granted Critical
Publication of CA2504751C publication Critical patent/CA2504751C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation d'agents capables d'inhiber l'action biologique du récepteur des glycocorticoïdes dans des procédés servant à traiter le reflux gastro-oesophagien pathologique.
CA2504751A 2002-11-05 2003-11-05 Procedes servant a traiter le reflux gastro-oesophagien pathologique Expired - Fee Related CA2504751C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42419902P 2002-11-05 2002-11-05
US60/424,199 2002-11-05
PCT/US2003/035341 WO2004041215A2 (fr) 2002-11-05 2003-11-05 Procedes servant a traiter le reflux gastro-oesophagien pathologique

Publications (2)

Publication Number Publication Date
CA2504751A1 CA2504751A1 (fr) 2004-05-21
CA2504751C true CA2504751C (fr) 2013-02-05

Family

ID=32312768

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2504751A Expired - Fee Related CA2504751C (fr) 2002-11-05 2003-11-05 Procedes servant a traiter le reflux gastro-oesophagien pathologique
CA2504697A Expired - Fee Related CA2504697C (fr) 2002-11-05 2003-11-05 Procedes pour traiter la migraine

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2504697A Expired - Fee Related CA2504697C (fr) 2002-11-05 2003-11-05 Procedes pour traiter la migraine

Country Status (6)

Country Link
US (2) US7361646B2 (fr)
EP (2) EP1581234A4 (fr)
JP (3) JP2006508951A (fr)
AU (2) AU2003291314B2 (fr)
CA (2) CA2504751C (fr)
WO (2) WO2004041214A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2012796A4 (fr) * 2006-05-02 2010-08-11 Corcept Therapeutics Inc Utilisation d'antagonistes des recepteurs de type ii des glucocorticoides pour traiter la depression de patients prenant de l'il-2
DK2114970T3 (da) 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer
EP2211845B1 (fr) * 2007-10-17 2017-02-22 Laboratoire HRA Pharma Antagonistes du recepteur glucocorticoide comme mifepristone traitement du syndrome de cushing
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
WO2009064819A2 (fr) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions pour le traitement de l'inflammation gastro-intestinale
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US20150209374A1 (en) 2014-01-29 2015-07-30 Faro Owiesy Composition and Method for Curing Migraine Headaches
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
KR20180052120A (ko) 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
CA3011728A1 (fr) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Diagnostic differentiel du syndrome de cushing ectopique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5250529A (en) * 1990-02-08 1993-10-05 Kos Pharmaceuticals, Inc. Method alleviating migraine headache with mast cell degranulation blocking agents
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US5697112A (en) * 1996-11-08 1997-12-16 Glaxo Wellcome Inc. Therapy pillow useful for treating gastroesophageal reflux disease (gerd) and other applications
US6166013A (en) * 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
UA74145C2 (uk) 1999-04-30 2005-11-15 Пфайзер Продактс Інк. Модулятори глюкокортикоїдного рецептора
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US20030148987A1 (en) * 2001-12-21 2003-08-07 Morris David J. Selective 11beta-HSD inhibitors and methods of use thereof

Also Published As

Publication number Publication date
AU2003291314A1 (en) 2004-06-07
EP1581234A4 (fr) 2007-09-12
JP2006508951A (ja) 2006-03-16
US7361646B2 (en) 2008-04-22
US20040132703A1 (en) 2004-07-08
JP2006507311A (ja) 2006-03-02
AU2003291314C1 (en) 2004-06-07
CA2504751A1 (fr) 2004-05-21
AU2003291322B2 (en) 2008-09-25
AU2003291322A1 (en) 2004-06-07
JP2011021044A (ja) 2011-02-03
WO2004041214A3 (fr) 2004-11-11
US20040167110A1 (en) 2004-08-26
EP1567167A2 (fr) 2005-08-31
CA2504697C (fr) 2012-03-13
US8450379B2 (en) 2013-05-28
EP1581234A2 (fr) 2005-10-05
AU2003291314B2 (en) 2007-07-26
CA2504697A1 (fr) 2004-05-21
WO2004041214A2 (fr) 2004-05-21
WO2004041215A3 (fr) 2004-11-04
WO2004041215A2 (fr) 2004-05-21
EP1567167A4 (fr) 2007-09-12

Similar Documents

Publication Publication Date Title
CA2504751C (fr) Procedes servant a traiter le reflux gastro-oesophagien pathologique
US20210128584A1 (en) Use of glucocorticoid receptor antagonists for the treatment of amyotrophic lateral sclerosis
US6680310B2 (en) Methods for preventing antipsychotic-induced weight gain
AU2002319665A1 (en) Methods for preventing antipsychotic-induced weight gain
US11103514B2 (en) Treatment of muscular dystrophy
US8097606B2 (en) Antiglucocorticoids for the treatment of catatonia
US20060052354A1 (en) Methods for treating migraine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201105